Searched for
MAIDEN PHARMA CASE
Pharmacy of the underworld: India's quality control diseaseToxic cough syrup has claimed more young lives in India. Despite past tragedies and international warnings, the nation's drug control syste...- Sresan Pharma, maker of Coldrif, broke multiple rules: OfficialsSresan Pharma, the manufacturer of Coldrif cough syrup linked to at least 16 child deaths, allegedly ignored numerous quality standards. A ...
- Lax testing fuelled wave of cough syrup poisoningsIn December 2019, tragedy struck the Himalayan mountains as Jafar Din's two-month-old son, Irfan, fell ill. Desperate to save him, Din boug...
- Cough syrup deaths case: The meds they bought were toxic. Now Gambian parents seek justiceAt least 70 children died from acute kidney injury in Gambia last year, cases the World Health Organization (WHO) linked to medicines made ...
- More India-made cough and cold syrups under WHO lens"To date this situation has impacted more than 20 products with two countries of origin (India & Indonesia) and more than 15 different manu...
- Seven medicines manufactured in India flagged ‘toxic’ by WHOWorld Health Organisation (WHO) spokesperson Christian Lindmeier, confirmed the development in an email to The Indian Express. The twenty m...
- Maiden Pharma Case: India probes bribery claim in toxic syrup testsIn an April 29 letter to the Anti-Corruption Bureau (ACB) in Haryana, a lawyer named Yashpal accused the state's drug controller, Manmohan ...
- India probes bribery claim in toxic syrup testsThe bribery allegation was one of about half a dozen claims of corruption by Yashpal against Taneja in the letter. Yashpal alleged Taneja h...
- Mystery middleman may be new clue in Gambian deaths related to Indian cough syrupThe owner of Goel Pharma Chem, which Indian drugs regulator claims supplied the propylene glycol used by Maiden Pharmaceuticals in its coug...
- Rupee outperforms most Asian peers as inflows riseA resumption of overseas investment flows into Indian stocks over the past couple of months has also propped up the rupee, resulting in the...
- Another Indian pharma manufacturer in news after WHO's substandard medicine alertThe alert was issued for a batch of substandard (contaminated) Guaifenesin Syrup TG Syrup. The substandard product was identified in the Ma...
- Maiden Pharma syrup caused child deaths: Gambian committee“The Select Committee is convinced that Maiden Pharmaceuticals Ltd is culpable and should be held accountable for exporting the contaminate...
- Maiden Pharma case: CDL finds no violation, calls WHO out for blaming company 'prematurely'Country's drug controller General of India (DCGI) has written a strongly worded letter to Rogerio Gaspar, Director, Regulation and Prequali...
- Nothing found yet to link Gambia deaths to syrup: ExpertsIn October, the state Drug Control Administration (DCA) had drawn samples of liquid products manufactured using propylene glycol from the S...
- Gambia issue: Report on cough syrup samples likely this weekThe World Health Organization (WHO) had earlier warned that the syrup may be linked to the deaths of children in Gambia following which Har...
- WHO alert on cough syrups 'alarming', there are missing links that need to be probed: ExpertThe World Health Organisation on Wednesday issued an alert, saying four "contaminated" and "substandard" cough syrups produced by Maiden Ph...
- US election results, Q2 earnings, Covid-19 cases among key factors that may drive market this weekQ2 earnings, Covid-19 cases and response to Gland Pharma IPO will be closely watched by investors.
- Colgate, GSK Pharma, Honeywell and Sanofi continue their outperformanceMNC stocks getting a premium due to their clean balance sheet and high level of transparency.
- Stocks in focus on 16 March 2018Here's a look at the top stocks that may hog the limelight in today's session:
- Budget 2014: Pharma sector left ailing for remedial measuresThe provisions and announcements in the budget are focussed towards the Government's commitment of "Health for All", especially "Free Drug ...
Load More
